Lv11
77 积分 2022-05-28 加入
The pharmacological basis for nonpeptide agonism of the GLP-1 receptor by orforglipron
22分钟前
待确认
Amylin receptors as therapeutic targets in obesity: Emerging peptide-based strategies
1个月前
已完结
Amylin: emergent therapeutic opportunities in overweight, obesity and diabetes mellitus
1个月前
已完结
Can amylin-based drugs upstage GLP-1 agonists?
1个月前
已完结
Discovery of BGM1812, a Novel Dual Amylin and Calcitonin Receptor Agonist for Obesity Treatment
3个月前
已完结
Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial
4个月前
已完结
Mechanism and reversal of drug-induced nephrotoxicity on a chip
4个月前
已完结
Toxicologic Pathology Forum: Opinion on Approaches for Reporting Toxic and Adverse Dose Levels in Nonclinical Toxicology Studies Supporting the Development of Anticancer Pharmaceuticals
4个月前
已完结
Successful Drug Development Despite Adverse Preclinical Findings Part 2: Examples
4个月前
已关闭
Successful Drug Development Despite Adverse Preclinical Findings Part 1: Processes to Address Issues and Most Important Findings
4个月前
已关闭
皖公网安备34019202002308
